


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of claims:

1. (Currently amended) A compound of formula (I)



including enantiomers, diastereomers, tautomers, and pharmaceutically acceptable salts, and solvates thereof wherein:

A, B, D, and E, ~~X and Y~~ are selected from N or C, J and K are C, X and Y are both N, and at least exactly one of A, B, D, and E, ~~X and Y~~ is N;

L is selected from O, NH and S, wherein L may be connected to any one of A, B, D, E, J, X, K or Y;

M is CH or N;

P is a bond or C=O, wherein P is connected to any one of J, X, K or Y;

Z is $-(CFG)R^2$ $-CT^1T^2-G-R^2$ where F is T^1 and T^2 are independently selected from O, $H[2]$, alkyl or substituted alkyl or T^1 and T^2 are taken together to form O, and G is alkyl, O or NH or none;

n is 0-4;

R^1 is selected from halogen, -CN, -CF₃, substituted alkyl, aryl and heteroaryl;

R^2 is a ~~heterocyclyl~~ heterocycloalkyl containing at least one N;

R^3 is selected from halogen, cyano, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl, wherein R^3 is connected to any one of A, B, D and E;

R^4 and R^5 are H;

or R⁴ and R⁵ may be taken together with the atoms to which they are attached to form a ring;
and

R¹⁰ is selected from H, alkyl, substituted alkyl, alkenyl, and substituted alkenyl[;]

~~or E and R¹⁰ may be taken together with the atoms to which they are attached to form a heteroaryl or heterocycloalkyl ring.~~

2. (Currently amended) A compound of claim 1 including enantiomers, diastereomers, tautomers, and pharmaceutically acceptable salts, ~~and solvates~~ thereof wherein:

A is N;

B, D and E are C;

Either of X or Y or both are N;

L is NH;

M is N;

n is 1;

R¹ is selected from halogen, -CN, -CF₃, substituted alkyl, aryl and heteroaryl;

R² is a ~~heterocyclyl~~ heterocycloalkyl containing at least one N; and

R¹⁰ is H.

3. (Currently Amended) A compound of claim 2 including enantiomers, diastereomers, tautomers, and pharmaceutically acceptable salts, ~~and solvates~~ thereof wherein:

L is connected to J;

P is a bond; and




P is connected to K.



4. (Currently Amended) A compound of claim 2 including enantiomers, diastereomers, tautomers, and pharmaceutically acceptable salts, ~~and solvates~~ thereof wherein:

L is connected to D; and

P is connected to J.

5. (Currently Amended) A compound of claim 2 including enantiomers, diastereomers, tautomers, and pharmaceutically acceptable salts, ~~and solvates~~ thereof selected from:





6[4]. (Original) A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

7[5]. (Canceled).

8[6]. (Currently Amended) A method for the treatment ~~or prevention~~ of asthma comprising: administering a therapeutically effective amount of the pharmaceutical composition of claim 2[4].

9[6]. (Currently Amended) A method for the treatment ~~or prevention~~ of rheumatoid arthritis comprising: administering a therapeutically effective amount of the pharmaceutical composition of claim 2[4].

10[7]. (Currently Amended) A method for the treatment ~~or prevention~~ of psoriasis comprising: administering a therapeutically effective amount of the pharmaceutical composition of claim 2[4].

11.^[8] (Currently Amended) A method for the treatment or prevention of solid organ transplant rejection comprising: administering a therapeutically effective amount of the pharmaceutical composition of claim 2^[4].

12.^[10] (Currently Amended) A method for the treatment ~~or prevention~~ of chronic obstructive pulmonary disease comprising: administering a therapeutically effective amount of the pharmaceutical composition of claim 2^[4].